“Pharmaceutical executives who recently made a major donation to an anti-marijuana legalization campaign claimed they were doing so out of concern for the safety of children — but their investor filings reveal that pot poses a direct threat to their plans to cash in on a synthetic cannabis product they have developed.”
Related Posts
Cannabinoid improves survival rates of mice with pancreatic cancer
- WOCredentials
- July 31, 2018
- 0
“Mice with pancreatic cancer that were treated with a naturally occurring constituent of medicinal cannabis alongside chemotherapy, survived almost three times longer than those treated with chemotherapy alone, a new […]
A pharma company that spent $500,000 trying to keep pot illegal just got DEA approval for synthetic marijuana
- WOCredentials
- March 29, 2017
- 0
“Insys Therapeutics, a pharmaceutical company that was one of the chief financial backers of the opposition to marijuana legalization in Arizona last year, received preliminary approval from the Drug Enforcement […]
The endocannabinoid system: A revolving plate in neuro-immune interaction in health and disease (2012)
- WOCredentials
- June 16, 2016
- 0
” Studies examining the effect of cannabinoid-based drugs on immunity have shown that many cellular and cytokine mechanisms are modulated by these agents, thus raising the hypothesis that these compounds […]